Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 3/2011

01.09.2011 | Materno-fetal Medicine

Influence of the vascular endothelial growth factor on the development of severe pre-eclampsia or HELLP syndrome

verfasst von: Stefanie Bussen, Dieter Bussen

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to compare the maternal serum concentrations of the vascular endothelial growth factor (VEGF) in patients whose pregnancies were complicated by pre-eclampsia or HELLP syndrome with those of healthy pregnant controls and to study its relationship with the hormonal and nutritive function of the placenta.

Methods

The study group consisted of 30 primaparae who suffered from either severe pre-eclampsia (n = 16) or from HELLP syndrome (n = 14). 30 healthy pregnant woman of the same gestational age served as control group. Maternal serum VEGF concentrations were determined by using a commercially available Sandwich immunoassay (Quantikine®, R&D Systeme, Wiesbaden, Germany). Estradiol, estriol and progesterone serum levels were measured by performing a radioimmunoassay (Biermann, Bad Nauheim, Germany).

Results

The mean serum VEGF concentration of the study group (172.0 ± 98.9 pg/ml) was significantly increased, compared with the mean serum VEGF concentration of the control group (41.4 ± 30.5 pg/ml) (U test: P < 0.001). In the subgroup of the study patients with HELLP syndrome, significantly lower VEGF levels were measured than in patients suffering from severe pre-eclampsia (109.2 ± 68.5 pg/ml vs. 219.0 ± 72.9. U test: P < 0.05). In all study and control patients, a significantly positive correlation between serum estradiol and VEGF concentration could be found (Spearman’s rank correlation: P < 0.05).

Conclusions

An increased placental expression due to local hypoxia and an increased extraplacental production, e.g., in endothelial cells of the fetal or maternal vascular system, in macrophages or in smooth muscle cells, could be discussed as causes for the raised serum VEGF concentration in patients suffering from severe pre-eclampsia or HELLP syndrome.
Literatur
1.
Zurück zum Zitat Yücesoy G, Ozkan S, Bodur H, Tan T, Caliskan E, Vural B, Corakci A (2005) Maternal and perinatal outcome in pregnancies complicated with hypertensive disorders of pregnancy: a seven year experience of a tertiary center. Arch Gynecol Obstet 273:43–49PubMedCrossRef Yücesoy G, Ozkan S, Bodur H, Tan T, Caliskan E, Vural B, Corakci A (2005) Maternal and perinatal outcome in pregnancies complicated with hypertensive disorders of pregnancy: a seven year experience of a tertiary center. Arch Gynecol Obstet 273:43–49PubMedCrossRef
2.
Zurück zum Zitat Al-Suleiman SA, Qutub HO, Rahman J, Rahman MS (2006) Obstetric admissions to the intensive care unit: a 12-year-review. Arch Gynecol Obstet 274:4–8PubMedCrossRef Al-Suleiman SA, Qutub HO, Rahman J, Rahman MS (2006) Obstetric admissions to the intensive care unit: a 12-year-review. Arch Gynecol Obstet 274:4–8PubMedCrossRef
3.
Zurück zum Zitat Kawabata I, Nakai A, Takeshita T (2006) Prediction of HELLP syndrome with assessment of maternal dual hepatic blood supply by using Doppler ultrasound. Arch Gynecol Obstet 274:303–309PubMedCrossRef Kawabata I, Nakai A, Takeshita T (2006) Prediction of HELLP syndrome with assessment of maternal dual hepatic blood supply by using Doppler ultrasound. Arch Gynecol Obstet 274:303–309PubMedCrossRef
4.
Zurück zum Zitat Ozer A, Kanat-Pektas M, Ozer S, Tapisiz OL, Zulfikaroglu EE, Damnisman N (2009) The effect of betametasone treatment on clinical and laboratory features of pregnant women with HELLP syndrome. Arch Gynecol Obstet 280:65–70PubMedCrossRef Ozer A, Kanat-Pektas M, Ozer S, Tapisiz OL, Zulfikaroglu EE, Damnisman N (2009) The effect of betametasone treatment on clinical and laboratory features of pregnant women with HELLP syndrome. Arch Gynecol Obstet 280:65–70PubMedCrossRef
5.
Zurück zum Zitat Gasem T, Al Jama FE, Burshaid S, Rahman J, Al Suleiman SA, Rahman MS (2009) Maternal and fetal outcome of pregnancy complicated by HELLP syndrome. J Matern Fetal Neonatal Med 22:1140–1143PubMedCrossRef Gasem T, Al Jama FE, Burshaid S, Rahman J, Al Suleiman SA, Rahman MS (2009) Maternal and fetal outcome of pregnancy complicated by HELLP syndrome. J Matern Fetal Neonatal Med 22:1140–1143PubMedCrossRef
6.
Zurück zum Zitat Ott J, Poschalko G, Zeisler H (2010) Severe early onset hemolysis, elevated liver enzyme, and low platelet-syndrome in 2 subsequent pregnancies: case report and review of the literature. Arch Gynecol Obstet 281:265–268PubMedCrossRef Ott J, Poschalko G, Zeisler H (2010) Severe early onset hemolysis, elevated liver enzyme, and low platelet-syndrome in 2 subsequent pregnancies: case report and review of the literature. Arch Gynecol Obstet 281:265–268PubMedCrossRef
7.
Zurück zum Zitat Young BC, Levine RJ, Karumanchi SA (2010) Pathogenesis of pre-eclampsia. Annu Rev Pathol 5:173–192PubMedCrossRef Young BC, Levine RJ, Karumanchi SA (2010) Pathogenesis of pre-eclampsia. Annu Rev Pathol 5:173–192PubMedCrossRef
8.
Zurück zum Zitat Myers LE, Baker PN (2002) Hypertensive diseases and pre-eclampsia. Curr Opin Obstet Gynecol 14:119–125PubMedCrossRef Myers LE, Baker PN (2002) Hypertensive diseases and pre-eclampsia. Curr Opin Obstet Gynecol 14:119–125PubMedCrossRef
9.
10.
Zurück zum Zitat Backe J, Bussen S, Steck T (1997) Significant decrease of maternal serum serotonin levels in singleton pregnancies complicated by severe pre-eclampsia or the HELLP-syndrome. Gynecol Endocrinol 11:405–409PubMedCrossRef Backe J, Bussen S, Steck T (1997) Significant decrease of maternal serum serotonin levels in singleton pregnancies complicated by severe pre-eclampsia or the HELLP-syndrome. Gynecol Endocrinol 11:405–409PubMedCrossRef
11.
Zurück zum Zitat Bussen S, Sütterlin M, Steck T (1999) Plasma endothelin and big endothelin levels in women with severe pre-eclampsia or HELLP-syndrome. Arch Gynecol Obstet 262:113–119PubMedCrossRef Bussen S, Sütterlin M, Steck T (1999) Plasma endothelin and big endothelin levels in women with severe pre-eclampsia or HELLP-syndrome. Arch Gynecol Obstet 262:113–119PubMedCrossRef
12.
Zurück zum Zitat Hristoskova S, Holzgrewe W, Zhong XY, Hahn S (2008) Macrophage migration inhibiting factor is elevated in pregnancy but not to a greater extent in pre-eclampsia. Arch Gynecol Obstet 274:25–28CrossRef Hristoskova S, Holzgrewe W, Zhong XY, Hahn S (2008) Macrophage migration inhibiting factor is elevated in pregnancy but not to a greater extent in pre-eclampsia. Arch Gynecol Obstet 274:25–28CrossRef
13.
Zurück zum Zitat Catarino C, Rebelo I, Belo L, Rocha S, Castro EB, Patricio B, Quintanilha A, Santos-Silva A (2009) Fetal and maternal angiogentic/anti-angiogenetic factors in normal and pre-eclamptic pregnancy. Growth Factors 27:345–351PubMedCrossRef Catarino C, Rebelo I, Belo L, Rocha S, Castro EB, Patricio B, Quintanilha A, Santos-Silva A (2009) Fetal and maternal angiogentic/anti-angiogenetic factors in normal and pre-eclamptic pregnancy. Growth Factors 27:345–351PubMedCrossRef
14.
Zurück zum Zitat Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, Gotsch F, Edwin SS, Gomez R (2009) A prospective cohort study of the value of maternal plasma concentration of angiogenetic and anti-angiogenetic factors in early and midtrimester in the identification of patients destined to develop pre-eclampsia. J Matern Fetal Neonatal Med 22:1021–1038PubMedCrossRef Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, Gotsch F, Edwin SS, Gomez R (2009) A prospective cohort study of the value of maternal plasma concentration of angiogenetic and anti-angiogenetic factors in early and midtrimester in the identification of patients destined to develop pre-eclampsia. J Matern Fetal Neonatal Med 22:1021–1038PubMedCrossRef
15.
Zurück zum Zitat Kalkunte S, Lai Z, Norris WE, Pietras LA, Tewari N, Boji R, Neubeck S, Markert UR, Sharma S (2009) Novel approaches for mechanistic understanding and predicting pre-eclampsia. J Reprod Immunol 83:134–138PubMedCrossRef Kalkunte S, Lai Z, Norris WE, Pietras LA, Tewari N, Boji R, Neubeck S, Markert UR, Sharma S (2009) Novel approaches for mechanistic understanding and predicting pre-eclampsia. J Reprod Immunol 83:134–138PubMedCrossRef
16.
Zurück zum Zitat Galazios G, Papazoglou D, Tsikouras P, Kolios D (2009) Vascular endothelial factor gene polymorphisms and pregnancy. J Matern Fetal Neonatal Med 22:371–378PubMedCrossRef Galazios G, Papazoglou D, Tsikouras P, Kolios D (2009) Vascular endothelial factor gene polymorphisms and pregnancy. J Matern Fetal Neonatal Med 22:371–378PubMedCrossRef
17.
Zurück zum Zitat Munaut C, Lorquet S, Pequeux C, Blacher S, Berndt S, Frankenne F, Foidart JM (2008) Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGF-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod 23:1407–1415PubMedCrossRef Munaut C, Lorquet S, Pequeux C, Blacher S, Berndt S, Frankenne F, Foidart JM (2008) Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGF-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod 23:1407–1415PubMedCrossRef
18.
Zurück zum Zitat Hoffmann P, Saoudi Y, Benharouga M, Graham CH, Schaal JP, Mazoumi C, Feige JJ, Alfaidy N (2009) Role of EG-VEGF in human placentation: physiological and pathological implications. J Cell Mol Med 13:2224–2235PubMedCrossRef Hoffmann P, Saoudi Y, Benharouga M, Graham CH, Schaal JP, Mazoumi C, Feige JJ, Alfaidy N (2009) Role of EG-VEGF in human placentation: physiological and pathological implications. J Cell Mol Med 13:2224–2235PubMedCrossRef
19.
Zurück zum Zitat Türkcüoglu I, Türkcüoglu P, Karabulut AB, Tasar A (2010) Vitreous vascular endothelial growth factor level during gestation. Arch Gynecol Obstet 281:417–421PubMedCrossRef Türkcüoglu I, Türkcüoglu P, Karabulut AB, Tasar A (2010) Vitreous vascular endothelial growth factor level during gestation. Arch Gynecol Obstet 281:417–421PubMedCrossRef
20.
Zurück zum Zitat Akolekar R, de Cruz J, Foidart JM, Munaut C, Nicolaides KH (2010) Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in pre-eclampsia. Prenat Diagn 30:191–197PubMedCrossRef Akolekar R, de Cruz J, Foidart JM, Munaut C, Nicolaides KH (2010) Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in pre-eclampsia. Prenat Diagn 30:191–197PubMedCrossRef
21.
Zurück zum Zitat Kupferminc MJ, Daniel Y, Englender T, Baram A, Many A, Jaffa AJ, Gull I, Lessing JB (1997) Vascular endothelial growth factor is increased in patients with pre-eclampsia. Am J Reprod Immunol 38:302–306PubMed Kupferminc MJ, Daniel Y, Englender T, Baram A, Many A, Jaffa AJ, Gull I, Lessing JB (1997) Vascular endothelial growth factor is increased in patients with pre-eclampsia. Am J Reprod Immunol 38:302–306PubMed
22.
Zurück zum Zitat Hayman R, Brockelsby J, Kenny L, Baker P (1999) Pre-eclampsia: the endothelium, circulating factors and VEGF. J Soc Gynecol Investig 6:3–10PubMedCrossRef Hayman R, Brockelsby J, Kenny L, Baker P (1999) Pre-eclampsia: the endothelium, circulating factors and VEGF. J Soc Gynecol Investig 6:3–10PubMedCrossRef
23.
Zurück zum Zitat Molvarec A, Szarka A, Walentin S, Szücs E, Nagy B, Rigó J (2010) Circulating angiogenetic factors determined by electrochemiluminescence in immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertension (in press). doi:10.1038/hr.2010.92 Molvarec A, Szarka A, Walentin S, Szücs E, Nagy B, Rigó J (2010) Circulating angiogenetic factors determined by electrochemiluminescence in immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertension (in press). doi:10.​1038/​hr.​2010.​92
24.
Zurück zum Zitat Akercan F, Cirpan T, Terek MC, Ozcakir HT, Giray G, Sagol S, Karadadas N (2008) The immunohistochemical evaluation of VEGF in placental biopsies of pregnancies complicated by pre-eclampsia. Arch Gynecol Obstet 272:109–114CrossRef Akercan F, Cirpan T, Terek MC, Ozcakir HT, Giray G, Sagol S, Karadadas N (2008) The immunohistochemical evaluation of VEGF in placental biopsies of pregnancies complicated by pre-eclampsia. Arch Gynecol Obstet 272:109–114CrossRef
25.
Zurück zum Zitat Sibai BM (1990) The HELLP syndrome: much ado about nothing? Am J Obstet Gynecol 162:911–915 Sibai BM (1990) The HELLP syndrome: much ado about nothing? Am J Obstet Gynecol 162:911–915
26.
Zurück zum Zitat Baker PN, Krasnow J, Roberts JM, Yeo KT (1995) Elevated serum levels of vascular endothelial growth factor in patients with pre-eclampsia. Obstet Gynecol 86:815–821PubMedCrossRef Baker PN, Krasnow J, Roberts JM, Yeo KT (1995) Elevated serum levels of vascular endothelial growth factor in patients with pre-eclampsia. Obstet Gynecol 86:815–821PubMedCrossRef
27.
Zurück zum Zitat Vuorela-Vepsäläien P, Alfthan H, Orpana A, Alitalo K, Stenman UH, Halmesmäki E (1998) Vascular endothelial growth factor is bound in amniotic fluid and maternal serum. Hum Reprod 14:1346–1351CrossRef Vuorela-Vepsäläien P, Alfthan H, Orpana A, Alitalo K, Stenman UH, Halmesmäki E (1998) Vascular endothelial growth factor is bound in amniotic fluid and maternal serum. Hum Reprod 14:1346–1351CrossRef
28.
Zurück zum Zitat Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845PubMedCrossRef Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845PubMedCrossRef
29.
Zurück zum Zitat Namiki A, Brogi E, Kearney M, Kim EA, Wu T, Couffinhal T, Vartcovski L, Inser JM (1995) Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 279:1189–1195 Namiki A, Brogi E, Kearney M, Kim EA, Wu T, Couffinhal T, Vartcovski L, Inser JM (1995) Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 279:1189–1195
30.
Zurück zum Zitat Ahmed A, Dunk C, Ahmad S, Khaliq A (2000) Regulation of placental vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) and soluble Flt-1 by oxygen—a review. Placenta 21:S14–S24CrossRef Ahmed A, Dunk C, Ahmad S, Khaliq A (2000) Regulation of placental vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) and soluble Flt-1 by oxygen—a review. Placenta 21:S14–S24CrossRef
31.
Zurück zum Zitat Helske S, Vuorela P, Carpen O, Hornig C, Weich H, Hamesmäki E (2001) Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 7:205–210PubMedCrossRef Helske S, Vuorela P, Carpen O, Hornig C, Weich H, Hamesmäki E (2001) Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 7:205–210PubMedCrossRef
32.
Zurück zum Zitat Ranheim T, Staff AC, Henrikson T (2001) VEGF mRNA is unaltered in decidual and placental tissues in pre-eclampsia at delivery. Acta Obstet Gynecol 80:93–98CrossRef Ranheim T, Staff AC, Henrikson T (2001) VEGF mRNA is unaltered in decidual and placental tissues in pre-eclampsia at delivery. Acta Obstet Gynecol 80:93–98CrossRef
33.
Zurück zum Zitat Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Atitalo K, Damsky C, Fisher S (2002) Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe pre-eclampsia and hemolysis, elevated liver enzymes and low platelet syndrome. Am J Pathol 60:1405–1423CrossRef Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Atitalo K, Damsky C, Fisher S (2002) Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe pre-eclampsia and hemolysis, elevated liver enzymes and low platelet syndrome. Am J Pathol 60:1405–1423CrossRef
34.
Zurück zum Zitat Bosio PM, Wheeler T, Anthony F, Conro R, O’Herlihy C, McKenna P (2001) Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance. Am J Obstet Gynecol 184:146–152PubMedCrossRef Bosio PM, Wheeler T, Anthony F, Conro R, O’Herlihy C, McKenna P (2001) Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance. Am J Obstet Gynecol 184:146–152PubMedCrossRef
35.
Zurück zum Zitat Brockelsby JC, Anthony FW, Johnson IR, Baker PN (2000) The effects of vascular endothelial growth factor on endothelial cells: a potential role in pre-eclampsia. Am J Obstet Gynecol 182:176–183PubMedCrossRef Brockelsby JC, Anthony FW, Johnson IR, Baker PN (2000) The effects of vascular endothelial growth factor on endothelial cells: a potential role in pre-eclampsia. Am J Obstet Gynecol 182:176–183PubMedCrossRef
36.
Zurück zum Zitat Reister F, Frank HG, Heyl W, Huppertz B, Kosanke W, Schröder P, Kaufmann P, Rath W (1997) Distribution of macrophages in the placental bed in pre-eclamptic patients. Placenta 18:A48–A49 Reister F, Frank HG, Heyl W, Huppertz B, Kosanke W, Schröder P, Kaufmann P, Rath W (1997) Distribution of macrophages in the placental bed in pre-eclamptic patients. Placenta 18:A48–A49
37.
Zurück zum Zitat Jelkmann W (2001) Pitfalls in measurements of circulating vascular endothelial factor. Clin Chem 47:617–623PubMed Jelkmann W (2001) Pitfalls in measurements of circulating vascular endothelial factor. Clin Chem 47:617–623PubMed
38.
Zurück zum Zitat Wheeler T, Evans PW, Anthony FW, Godfrey KM, Howe DT, Osmond C (1999) Relationship between maternal serum vascular endothelial growth factor concentration in early pregnancy and fetal and placental growth. Hum Reprod 14:1619–1623PubMedCrossRef Wheeler T, Evans PW, Anthony FW, Godfrey KM, Howe DT, Osmond C (1999) Relationship between maternal serum vascular endothelial growth factor concentration in early pregnancy and fetal and placental growth. Hum Reprod 14:1619–1623PubMedCrossRef
39.
Zurück zum Zitat Cooper JC, Sharkey AM, Charnock-Jones DS, Palmer CR, Smith SK (1996) VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 103:1191–1196PubMedCrossRef Cooper JC, Sharkey AM, Charnock-Jones DS, Palmer CR, Smith SK (1996) VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 103:1191–1196PubMedCrossRef
40.
Zurück zum Zitat Bányász I, Szabó S, Bokodi G, Vannay A, Vásárhelyi B, Szabó A, Tulassay T, Rigó J Jr (2006) Genetic polymorphisms of vascular endothelial growth factor in severe pre-eclampsia. Mol Hum Reprod 12:233–236PubMedCrossRef Bányász I, Szabó S, Bokodi G, Vannay A, Vásárhelyi B, Szabó A, Tulassay T, Rigó J Jr (2006) Genetic polymorphisms of vascular endothelial growth factor in severe pre-eclampsia. Mol Hum Reprod 12:233–236PubMedCrossRef
41.
Zurück zum Zitat Nagy B, Savli H, Molvarec A, Várkonyi T, Rigó B, Hupuczi P, Rigó J Jr (2008) Vascular endothelial growth factor (VEGF) polymorphisms in HELLP syndrome patients determined by quantitative real-time PCR and melting curve analyses. Clin Chim Acta 389:126–131PubMedCrossRef Nagy B, Savli H, Molvarec A, Várkonyi T, Rigó B, Hupuczi P, Rigó J Jr (2008) Vascular endothelial growth factor (VEGF) polymorphisms in HELLP syndrome patients determined by quantitative real-time PCR and melting curve analyses. Clin Chim Acta 389:126–131PubMedCrossRef
42.
Zurück zum Zitat Milne F, Redman C, Walker J, Baker P, Black R, Blincowe J, Cooper C, Fletcher G, Jokinen M, Moran PA (2009) Assessing the onset of pre-eclampsia: summary of the pre-eclampsia guideline (PRECOG II). BMJ 339:3129–3131CrossRef Milne F, Redman C, Walker J, Baker P, Black R, Blincowe J, Cooper C, Fletcher G, Jokinen M, Moran PA (2009) Assessing the onset of pre-eclampsia: summary of the pre-eclampsia guideline (PRECOG II). BMJ 339:3129–3131CrossRef
43.
Zurück zum Zitat Huda SS, Freeman DJ, Nelson SM (2009) Short- and long-term strategies for the management of hypertensive disorders of pregnancy. Expert Rev Cardiovasc Ther 7:1581–1594PubMedCrossRef Huda SS, Freeman DJ, Nelson SM (2009) Short- and long-term strategies for the management of hypertensive disorders of pregnancy. Expert Rev Cardiovasc Ther 7:1581–1594PubMedCrossRef
44.
Zurück zum Zitat Evans PW, Wheeler T, Anthony F, Osmond C (1998) A longitudinal study of maternal serum vascular endothelial growth factor in early pregnancy. Hum Reprod 13:1057–1060PubMedCrossRef Evans PW, Wheeler T, Anthony F, Osmond C (1998) A longitudinal study of maternal serum vascular endothelial growth factor in early pregnancy. Hum Reprod 13:1057–1060PubMedCrossRef
Metadaten
Titel
Influence of the vascular endothelial growth factor on the development of severe pre-eclampsia or HELLP syndrome
verfasst von
Stefanie Bussen
Dieter Bussen
Publikationsdatum
01.09.2011
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 3/2011
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-010-1704-x

Weitere Artikel der Ausgabe 3/2011

Archives of Gynecology and Obstetrics 3/2011 Zur Ausgabe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.